ICLs: Investigators finding robust and stable results over long term

Digital EditionOphthalmology Times: October 15, 2020
Volume 45
Issue 17

Physicians often use lenses due to abnormal corneal topography or high myopia

This article was reviewed by Kyle T. Packer, MD

Posterior chamber implantation of implantablecollamer lenses (ICLs) provided robust, stable results in a young population during an 11-year period.

Most of the data are significant out to 8 years of follow-up, according to Kyle T. Packer, MD, who is with the US Army and practicing in Hanover, New Hampshire.

The results were garnered from a retrospective longitudinal study of 3004 eyes implanted with the ICLs at a US military treatment facility from 2008 to 2019.

Related: Robotics: Allowing surgeons to perform the seemingly impossible

All patients underwent standard refractive procedures and measurements preoperatively and postoperatively.

The median patient age was 25 years; 67% of patients were men. The median baseline spherical equivalent (SE) was –5.87 D.

Packer reported that the mean SE turned slightly myopic over the first 7 years postoperatively. The mean uncorrected visual acuity (UCVA) exceeded 20/25 and the mean best-corrected visual acuity (BCVA) exceeded 20/20 in all patients out to postoperative year 7.

ICLs were implanted in patients because of the presence of abnormal topography or moderate or high levels of myopia.

A comparison of the preoperative and postoperative BCVA showed that about 40% of patients had a gain of a minimum of 1 line of BCVA during the first year after implantation, indicating the safety of the ICLs.

Related: Physicians' treatment decisions are reinforced with good data

The endothelial cell count decreased over time postoperatively compared with the baseline, which resulted in a significant overall decrease of 14.4% from baseline to the 5-year time point.

Patients had a significant increase in the IOP to the 1-year time point, and decreased from years 2 through 8.

The vault was estimated as a percentage of the corneal thickness. Low vaults were defined as less than 50% of the corneal thickness, ideal vaults from 51% to 200%, and high vaults over 200%. In this patient population, most vaults were considered ideal.

“The trend over time was a decrease in the vault size, especially after year 7, with no vault size over 157% of the corneal thickness,” Packer said.

Adverse events occurred in 1.2% during the 11-year follow-up, which included the formation of visually relevant cataracts, glaucoma, retinal detachment, and traumatic incision opening. The ICLs were removed in 4.5% of eyes in most cases because of low vaults.

Related: Persistent retinal detachment connected to retinoblastoma

Physicians often use lenses due to abnormal corneal topography or high myopiaThe main takeaways from this study were the following:

(1) ICLs were implanted because of abnormal corneal topography or high myopia;
(2) refractive results associated with the ICLs were robust and stable during the long-term follow-up;
(3) vault size decreased over time, which suggested an increased risk of cataract formation after 7 years;
(4) a decrease in the mean endothelial cell count of about 14.4% at the fifth postoperative year suggested that another study is needed to assess the long-term clinical significance.

Recent Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
© 2024 MJH Life Sciences

All rights reserved.